Literature DB >> 1637134

Multifocal inflammatory leukoencephalopathy with 5-fluorouracil and levamisole.

C C Hook1, D W Kimmel, L K Kvols, B W Scheithauer, P A Forsyth, J Rubin, C G Moertel, M Rodriguez.   

Abstract

A cerebral demyelinating disease developed in 3 patients during adjuvant therapy with 5-fluorouracil and levamisole for adenocarcinoma of the colon. None of the patients had evidence of metastatic disease or prior neurological disease. The duration of chemotherapy before onset of neurological symptoms ranged from 15 to 19 weeks. The total dose of 5-fluorouracil was 9.7 to 15.7 gm. The total dose of levamisole was 2.7 to 3.75 gm. Two patients presented with a subacute (2-3 weeks) progressive decline in mental status and ataxia. The third patient had two unexplained episodes of loss of consciousness. In each, magnetic resonance imaging with gadolinium demonstrated prominent multifocal enhancing white matter lesions. Cerebral biopsy was performed stereotaxically in 2 patients. The morphological features were those of active demyelinating disease. The myelin loss was associated with numerous dispersed as well as vasocentric macrophages, sparing of axons, and perivascular lymphocytic inflammation. Electron microscopy confirmed the light microscopic findings. All 3 patients improved after cessation of chemotherapy and a short course of corticosteroid therapy. Our patients represent the first reported examples of an inflammatory leukoencephalopathy associated with the administration of 5-fluorouracil and levamisole. This syndrome may represent the pathological basis for 5-fluorouracil neurotoxicity, although we cannot completely exclude the role of levamisole.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1637134     DOI: 10.1002/ana.410310306

Source DB:  PubMed          Journal:  Ann Neurol        ISSN: 0364-5134            Impact factor:   10.422


  21 in total

1.  Case files of the New York City poison control center: paradichlorobenzene-induced leukoencephalopathy.

Authors:  Stephanie H Hernandez; Sage W Wiener; Silas W Smith
Journal:  J Med Toxicol       Date:  2010-06

2.  Reversible posterior leukoencephalopathy syndrome induced by bevacizumab plus chemotherapy in colorectal cancer.

Authors:  Wei Wang; Li-Rong Zhao; Xiu-Qiang Lin; Fen Feng
Journal:  World J Gastroenterol       Date:  2014-06-07       Impact factor: 5.742

3.  Acute disseminated encephalomyelitis: a follow-up study in Taiwan.

Authors:  C-H Lin; J-S Jeng; S-T Hsieh; P-K Yip; R-M Wu
Journal:  J Neurol Neurosurg Psychiatry       Date:  2006-10-06       Impact factor: 10.154

4.  Focal dystonia after chemotherapy: a case series.

Authors:  A Brashear; E Siemers
Journal:  J Neurooncol       Date:  1997-09       Impact factor: 4.130

5.  Clinical-radiological-pathological spectrum of central nervous system-idiopathic inflammatory demyelinating disease in the elderly.

Authors:  W Oliver Tobin; Chiara Costanzi; Yong Guo; Joseph E Parisi; Stephen D Weigand; Claudia F Lucchinetti
Journal:  Mult Scler       Date:  2016-10-19       Impact factor: 6.312

6.  Adverse reactions with levamisole vary according to its indications and misuse: A systematic pharmacovigilance study.

Authors:  Jérémy T Campillo; Céline Eiden; Michel Boussinesq; Sébastien D S Pion; Jean-Luc Faillie; Cédric B Chesnais
Journal:  Br J Clin Pharmacol       Date:  2021-09-15       Impact factor: 3.716

7.  Delayed, transient encephalopathy after marrow transplantation: case reports and MRI findings in four patients.

Authors:  H I Tahsildar; B F Remler; R J Creger; B W Cooper; S M Snodgrass; R W Tarr; H M Lazarus
Journal:  J Neurooncol       Date:  1996-03       Impact factor: 4.130

Review 8.  Seizures and epilepsy in oncological practice: causes, course, mechanisms and treatment.

Authors:  Gagandeep Singh; Jeremy H Rees; Josemir W Sander
Journal:  J Neurol Neurosurg Psychiatry       Date:  2007-04       Impact factor: 10.154

Review 9.  Adjuvant therapy for completely resected stage II colon cancer.

Authors:  Alvaro Figueredo; Megan E Coombes; Som Mukherjee
Journal:  Cochrane Database Syst Rev       Date:  2008-07-16

10.  Late mortality and levamisole adjuvant therapy in colorectal cancer.

Authors:  R T Chlebowski; L Lillington; J S Nystrom; J Sayre
Journal:  Br J Cancer       Date:  1994-06       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.